The scientific evidence shows that allografts are the second best option to patient's own bone compared to other bone substitutes.1 MinerOss™ A is a processed allogenic bone tissue that offers proven, reliable, and predictable surgical outcomes comparable to autologous bone harvested from intra-oral donor sites.
MinerOss™ A is an allograft predominantly derived from human donor femoral heads post hip replacement surgery. The donor tissue is thoroughly inspected and undergoes a strict serological screening protocol.
Thanks to its natural bone composition consisting of mineralised human collagen, MinerOss™ A shows a high biologic regeneration capability in combination with natural remodelling. Therefore, MinerOss™ A is an excellent alternative to autologous bone, meaning that there is no need for an intraoral surgical donor site, which reduces morbidity for the patient.
MinerOss™ A undergoes high safety standards in its production process and guarantees a 5-year shelf life at 5°C - 30°C.
Large bone defects where one bone wall is maintained can be restored to replace missing or inadequate bone tissue, or for filling or stabilizing bone defects by using MinerOss™ A in combination with a collagen membrane.
Regeneration of extraction sockets
Filling the socket with MinerOss™ A in combination with collagen membrane regenerates bone and so retains the volume and shape of the bone over time.
Regeneration of periodontal osseous defects
A tooth with a good prognosis can be retained by regenerating lost bone, with the support of biomaterials such as MinerOss™ A in combination with collagen membrane.
Regeneration of gaps between alveolar wall and dental implants
MinerOss™ A is applied to the defect to support bone regeneration.
After crude removal of surrounding soft tissue, fat and cartilage, the donor tissue is brought into its final shape.
The defatting of the donor tissue allows moderate penetration of solvents during subsequent processing.
A treatment with alternating durations of diethyl ether and ethanol leaches out cellular components and denatures non-collagenic proteins, thereby inactivating potential viruses.
An oxidative treatment further denatures persisting soluble proteins, thereby eliminating potential antigenicity.
Freeze-drying preserves the natural structure of the tissue and maintains a residual moisture of <10%, allowing quick rehydration and easy handling.
Double packing and final sterilization by gamma-irradiation guarantees a 5-year shelf-life at 5°C - 30°C.
The scientific evidence shows that allografts are the second-best option to patient's own bone compared to other bone substitutes.1
Natural remodelling into vital new bone.3, 7
After thorough donor anamnesis, maximum safety is assured via a series of strict serological testing combined with C+TBA´s Allotec® purification procedure and radiological sterilization.
First, serology and nucleic acid tests (NAT) are performed to identify infections before antibodies are detected in the blood. Potential viruses are inactivated, and bacteria destroyed during Allotec® purification procedure where non-collagenic proteins are denatured.
An oxidative treatment is then used to denature persisting soluble proteins and eliminate potential antigenicity. Finally, the tissue undergoes dehydration via a lyophilization technique that facilitates the sublimation of frozen water from solid phase to gas phase.
This stage preserves the material’s structural integrity. The lyophilization process is an accepted and well documented procedure that preserves structural properties while improving graft incorporation.5, 6
The microscopic pores within the material ensure rapid rehydration of the tissue. The final sterilization by gamma irradiation guarantees a sterility assurance level (SAL) of 10-6 while ensuring structural and functional integrity of the product and its packaging.
Barbeck et al. Materials 2019, 12, 3234.
Kloss et al. Clin Case Rep. 2020, 8, 5.
Kloss et al. Clin Oral Implants Res. 2018, 29, 1163
Nissan et al. Journal of Biomedical Materials Research 2011, 97, 509.
Schlee et al. Head & Face Medicine 2014, 10, 21.
Schmitt et al. Clin Oral Implants Res. 2013, 24, 576.
Solakoglu et al. Clin Implant Dent Relat Res. 2019, 21, 1002-1016.
Trajkovski et al. Materials 2018, 11(2).
Tunkel et al. Clinical Case Reports 2020, 00:1-13.
Wang et al. J.Periodont.2019. Blocks, Materials 2019, 12, 3234
Wen et al. J. Periodont. 2019, 1, 734.
Not all products are available in all markets.